Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Non-Current Deffered Revenue (2018 - 2025)

Historic Non-Current Deffered Revenue for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $4.2 million.

  • Arcturus Therapeutics Holdings' Non-Current Deffered Revenue fell 6836.11% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year decrease of 6836.11%. This contributed to the annual value of $12.6 million for FY2024, which is 7034.07% down from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' Non-Current Deffered Revenue stood at $4.2 million, which was down 6836.11% from $8.8 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Non-Current Deffered Revenue ranged from a high of $42.5 million in Q4 2023 and a low of $4.2 million during Q3 2025
  • Moreover, its 5-year median value for Non-Current Deffered Revenue was $11.3 million (2024), whereas its average is $15.2 million.
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' Non-Current Deffered Revenue skyrocketed by 70924.89% in 2023 and then plummeted by 7034.07% in 2024.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Non-Current Deffered Revenue stood at $19.9 million in 2021, then increased by 0.7% to $20.1 million in 2022, then surged by 111.73% to $42.5 million in 2023, then crashed by 70.34% to $12.6 million in 2024, then crashed by 66.52% to $4.2 million in 2025.
  • Its last three reported values are $4.2 million in Q3 2025, $8.8 million for Q2 2025, and $9.6 million during Q1 2025.